It is well known that fibrous dysplasia (FD) is characterized by the presence of activating mutations involving Gnucleotide binding protein-a subunit (GNAS) involving codon R201 and rarely codon 227 with a mutation frequency between 45% and 93%. Herein, we investigate the sensitivity of detection of GNAS mutations in exons 8 and 9 using a standard and a highly sensitive locked nucleic acid polymerase chain reaction (LNA-PCR) sequencing in 52 cases of FD. In view of the recent report of GNAS mutations in a small number of low-grade osteosarcomas, we also tested in addition 12 cases of low-grade osteosarcomas. GNAS exon 8 mutations p.R201H (31%), p.R201C (15%), and p.R201S (2%) were identified in 50% of FD cases. LNA-PCR sequencing identified only 1 positive case within the mutation negative cases tested by standard PCR and Sanger sequencing. No mutations were identified in any of the low-grade osteosarcomas by standard and LNA-PCR sequencing. There was no association between age, site, size, specimen type, and mutational status. No exon 9 or codon 227 mutations were identified in any of tested cases. There was a significant difference in the sensitivity of the assay between decalcified and nondecalcified FDs (31% vs. 70%, P = 0.002). LNA-PCR has no added value in enhancing detection sensitivity for GNAS mutations in FD. In addition to decalcification, innate somatic mosaicism contributes to the decreased sensitivity in mutation detection.
F ibrous dysplasia (FD) is a benign medullary osteofibrous lesion that may involve one (monostotic FD) or more (polyostotic FD) bones. FD occurs in children and adults and affects all populations with an equal sex distribution. 1 FD may occur in isolation or as a part of McCune-Albright syndrome, which includes endocrine abnormalities, cafe´-au-lait pigmented skin lesions, and FD. 2 Microscopically, FD has biphasic morphology with both fibrous and osseous components. The fibrous component consists of cytologically bland spindle cells with low mitotic rate blending with and surrounding the osseous component. The latter shows irregular curvilinear trabeculae of woven bone. Typically, osteoblastic rimming of the bony trabeculae is absent. G-nucleotide binding protein-a subunit (GNAS) gene encodes the stimulatory G-protein a-subunit (Gsa), which serves as a ubiquitously expressed signal transducer that transmits hormonal and growth factor signals to effector proteins. The most well-characterized function of GNAS is activation of the membrane-associated enzyme adenylate cyclase, which stimulates the production of cyclic adenosine monophosphate (cAMP) and can activate protein kinase A. Mutations that occur at GNAS codons 201 (exon 8) or 227 (exon 9) have been shown to constitutively activate Gsa and therefore lead to constitutive cAMP signaling. 3 Studies showed that this constitutive signaling leads to increased cAMP in osteoblastic cells and impedes their normal differentiation. This confers the spindle cell morphology seen in FD and the immature partially formed bone trabeculae. [4] [5] [6] Over the last decade, GNAS mutational analysis has been used an ancillary test in challenging cases of FD. Studies have shown that GNAS mutation occur in FD with a frequency ranging from 45% to 100%. 7, 8 The technologies used to detect these mutations from paraffin-embedded tissues and frozen samples, range from traditional Sanger sequencing (requiring 25% mutant allele frequency) to more sensitive pyrosequencing (detects 1% to 2% mutant allele frequency). 8, 9 Herein, we report our institutional experience with GNAS mutational analysis in FD taking into consideration the effect of decalcification treatment. In addition, we investigate the added value of locked nucleic acid polymerase chain reaction (LNA-PCR) sequencing method in enhancing the assay's sensitivity. In addition, we have investigated a series of low-grade osteosarcomas for the presence of GNAS mutations with LNA-PCR sequencing.
MATERIALS AND METHODS

Patient Selection
Institutional pathology database was reviewed to identify patients with FD treated at our center over a 20year period. Sixty cases were selected. Only cases with the final diagnosis of "fibrous dysplasia" in Pathology database were included. Eight cases were excluded after pathologic examination due to atypical histologic and/or imaging features. Twelve cases of low-grade paraosteal osteosarcoma were also included.
DNA Extraction
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue blocks using DNeasy Tissue kit (Qiagen, Valencia, CA), following the manufacturer's protocol.
GNAS Mutational Analysis by Standard-PCR Sanger Sequencing and LNA-PCR Sequencing
GNAS exons 8 and 9 were amplified using the following forward and reverse primers: GNAS-Ex8F, 5 0 -GTAAAACGACGGCCAGT-3 0 ; GNAS-Ex8R, 5 0 -CAG GAAACAGCTATGACC-3 0 ; GNAS-Ex9F, 5 0 -GTAAAA CGACGGCCAGT-3 0 , and GNAS-Ex9R, 5 0 -CAGGAA ACAGCTATGACC-3 0 ( Fig. 1 ). Forward and reverse primers were M13 tailed to facilitate Sanger sequencing. All samples were tested in duplicate. The PCR amplification was performed in a final volume of 50 mL containing 100 to 200 ng of genomic DNA, 1Â JumpStart ReadyMix REDTaq DNA (Sigma P-0982), and forward and reverse primers (20 pmol each) for standard PCR. For the LNA-PCR reaction, 20 pmol of LNA probe (5 0 -G+G+A+ C+A+C+G+GC+AGCG/3InvdT/) complementary to the wild-type (WT) GNAS exon 8 sequence ( Fig. 1A ) was added to the reaction ( Fig. 1 ). Briefly, LNAs are nucleic acid analogs that contain a 2 0 -O to 4 0 -C-methylene bridge in the ribose moiety. LNA bases get incorporated into WT DNA oligonucleotide, which increases the thermal stability of DNA/probe heteroduplexes and as a result suppresses the WT allele amplification leading to preferential amplification of the mutant allele if present. The sensitivity achieved by this method is in the range of 0.5% to 1% detection of the mutant allele in any given sample ( 10,11 ) (see below).
The PCR cycling parameters included initial denaturation at 941C for 2 minutes, 42 cycles of denaturation at 941C (0 s), annealing at 601C (30 s), and extension at 721C (2 min), followed by a final extension at 721C (10 min). The PCR products of GNAS exons 8 (272 bp) and 9 (237 bp) were separated on a 3% agarose gel and visualized by ethidium bromide staining. All PCR products were purified using Spin Columns (Qiagen) and sequenced in both directions with forward M13F2: 5 0 -"GTAAAACGACGGCCAGT-3 0 and reverse M13R2: 5 0 -CAGGAAACAGCTATGACC"-3 0 primers using the BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems), according to the manufacturer's protocol on an ABI3730XL DNA sequencer running ABI Prism DNA Sequence Analysis Software. The GNAS reference sequence and the positions of the primers used in this assay are shown in Figure 1 .
Technical Sensitivity of Standard and LNA-PCR Sequencing Methods
The sensitivity study for GNAS sequencing analysis was performed by using 6 serial dilutions (50%, 25%, 12.5%, 6.25%, 3%, and 1.5%) from a known positive case harboring the common p.R201C mutation in exon 8 and mixed into normal DNA (Fig. 2 ).
Statistical Analysis
Pearson correlation test w 2 and Fisher exact test were used to study correlation between different covariables. Z test was used to compare proportions. P Student test was used to compare different numerical covariables. A P value of <0.05 was considered significant. Graph pad prism software package 6.0 was used for data analysis.
RESULTS
Clinical and Pathologic Findings
Clinical and pathologic data related to the 52 patients and tumors in the study group is shown in Table 1 . Comparison electropherograms: standard versus LNA-PCR assay sensitivity for GNAS exon 8 mutations. Serial dilutions of mutant DNA from a known positive case admixed with normal DNA from a nonmutated case to evaluate sensitivity of GNAS direct sequencing. %M denotes percent of mutant DNA. The tested sample showed about 50% of tumor cells based on peak height on the forward and reverse sequences, so the 50% dilution represent 25% of tumor DNA and so forth. LNA-PCR: the addition of 0.4 mM of locked oligonucleotide (LNA) blocks the amplification of the wild-type allele in the PCR reaction allowing the mutant allele to amplify. LNA-PCR indicates locked nucleic acid polymerase chain reaction.
Two of the FD group cases showed extensive adipocytic differentiation with myxoid and fibrous background consistent with the diagnosis of "liposclerosing fibromyxoid tumor," a variant of classic FD. In addition, 2 cases showed an associated desmoplastic fibroma (Fig. 3) . The low-grade osteosarcoma group included 11 surface low-grade parosteal osteosarcoma and 1 central lowgrade osteosarcoma. Three of the parosteal osteosarcomas showed evidence of high-grade dedifferentiation GNAS Exons 8 and 9 Mutations in the FD and Osteosarcoma Groups GNAS mutations in the R201 residue were detected by Sanger sequencing in 26 tested cases (50%) including 17 nondecalcified and 9 decalcified specimens, respectively. The CGT > CAT p.R201H mutation was the most frequently detected mutation (n = 17) followed by the CGT > TGT p.R201C mutation (n = 8). One additional mutation leading to substitution of the arginine residue with serine (p.R201S) was detected in 1 case (Table 1) . Cases which were negative by standard-PCR/ Sanger sequencing (n = 26, 50%) were tested for exon 8 mutation with LNA-PCR/Sanger sequencing method and exon 9 mutations standard-PCR sequencing. Except for 1 case which showed positive CGT > TGT, p.R201C mutation the rest of the tested cases were negative by LNA-PCR for GNAS exon 8 and no mutations were found in exon 9 by standard-PCR sequencing in these cases. None of the tested osteosarcoma tumors showed any mutations in GNAS exon 8 using standard (n = 12) and LNA-PCR sequencing methods (n = 8). No GNAS exon 9 sequencing was performed on these case ( Fig. 4 ).
Technical Sensitivity of Standard Sanger Sequencing and the LNA-PCR Sequencing
The results of the serial dilutions are shown in Figure 2 and summarized in Table 2 . On the basis of these results; the technical sensitivity for standard-PCR sequencing and the LNA-PCR sequencing is 12.5% and 1.5%, respectively.
Correlation of Different Clinicopathologic Variables With Mutational Status
No significant correlation was identified between the mutational status and any of the tested variable including, type of specimen, average size, site (long vs. flat bone), and histologic subtype ( Table 3 ). There was a significant difference in the sensitivity of the assay between decalcified and nondecalcified FDs (31% vs. 70%, P = 0.002).
DISCUSSION
GNAS gene is located on chromosome 20q13.3. The gene products are derived from the use of multiple promoters and first exons that splice onto a common set of downstream exons (exons 2 to 13). 12 Numerous splicing products are generated during GNAS transcription. The major product is a-subunit of the heterotrimeric G-protein complex (Gsa). It is generated by splicing occurring at the most downstream promoter at exon 1. 13 Gsa is ubiquitely expressed and interacts with numerous hormonal as well as other transmembrane receptors to adenylyl cyclase and is required for the receptor-stimulated intracellular cAMP production. 12, 13 Gsa expression is biallelic in most tissues including the bone; however, a small subset of tissues such as renal proximal tubules, pituitary, gonads, and thyroid expresses Gsa predominantly from the maternal allele. 12, 13 FD is characterized by activating missense mutations of the GNAS gene, encoding the subunit of the stimulatory G. These mutations occur postzygotically leading to a focal somatic mosaic state within the lesional tissue itself. 14, 15 This mechanism allows understanding the nonhereditary pattern of presentation in FD and the coexistence of a normal and "abnormal" genotype within the same lesional cell population. 16 Recent studies showed that activating GNAS mutations disrupt a pathway that is required for skeletal stem cell self-renewal and development of fibrous disease. As such, mutant cells fail to regenerate and die, whereas residual normal stem cells selectively survive. This leads to progressive remodeling that can replace dysplastic bone into normal bone over time. 16 FD can be a challenging diagnosis even for experienced bone pathologists as it can present with overlapping features with low-grade central osteosarcoma. Distinguishing between these 2 entities is critical as it carries major implications for patient management. Although diagnosis can be achieved by correlation of radiologic and histopathologic findings, overlapping features can be seen in some cases necessitating molecular testing. Hence, over the last decade, GNAS mutations have emerged as a useful ancillary molecular test in diagnosing FD. Two main nucleotide substitutions in codon 201 have been identified within exon 8 of the GNAS gene. These mutations lead to the replacement of an arginine by a histidine (R201H) or a cysteine (R201C). 7, 8 In rare cases, serine (R201S), leucine (R201L), and glycine (R201G) substitutions have been reported. [17] [18] [19] Exceptional cases of FD have been linked to mutation in exon 9, leading to the substitution of the glutamine at position 227 by a leucine (Q227L), an arginine (Q227R), a lysine (Q227K), or a histidine (Q227H). 20 All mutations lead to constitutive Gsa adenylate cyclase activity with overproduction of cAMP in dysplastic cells. 3 Several studies have reported variable sensitivity with different molecular detection methods for GNAS exon 8 mutations. In a seminal meta-analysis study by Lee and colleagues, the authors reviewed 9 series from different countries over a 14-year period. They reported a GNAS exon 8 activating mutation incidence rate of 71.9% of across studies. The authors' institutional experience with 48 FD cases yielded a positive rate of 58.3%. 8 In a recent study by Tabareau-Delalande and colleagues, the authors reported their experience with a series of 51 cases of FD using parallel high-resolution melting, allelespecific PCR, followed by standard Sanger sequencing. Their series yielded a GNAS exon 8 activating mutationpositive rate of 45%. This is similar to the range of what was reported by Lee and colleagues and lower than that obtained from the meta-analysis of different studies. 3, 7 Our series showed similar results to the 2 previously cited studies with a positive rate of 50% with inclusion of 29 decalcified and 23 nondecalcified cases. The sample size is an important factor that can introduce a significant sample size bias; indeed the highest sensitivities reported in the literature (positive rate of 100%) are from 4 different studies which included <10 patients each. 6, 18, 21, 22 Of note, each of these studies used a different detection method including restriction fragment analysis with standard sequencing or peptide nucleic acid. The number of samples studied, the specimen pretreatment (decalcification vs. no decalcification), the decalcification methods, and detection methods used are all important issues to consider when analyzing results from various studies. These factors may explain the differences seen between the meta-analysis results and our results. One of the most sensitive methods described for GNAS mutation detection is pyrosequencing. In a recent series of 24 cases of FD by Liang et al, 9 the authors reported a clinical sensitivity of 96% and an analytical sensitivity of 95% for their assay. This high sensitivity and specificity has not been reported in other series and was not seen in our group using a highly sensitive technique such as LNA-PCR sequencing. When choosing a mutation detection method for clinical DNA testing, sensitivity is one of the major points to consider. Direct sequencing still remains the gold standard method for mutation analysis. Yet, it requires a relatively high amount of mutant DNA of >20% in the total DNA population. LNA-PCR sequencing is a useful method to lower this threshold by amplifying selectively low copy number of mutant alleles increasing the sensitivity of the sequencing assay. In a study by Lietman and colleagues, the authors reported a very high sensitivity for this method. They report a threshold of detection of 1 mutant GNAS allele of 1000 to 5000 cells. 18 However, in their study, DNA was extracted from peripheral blood of patients McCune-Albright syndrome and not FD tissue samples. In our study, we aimed to investigate whether LNA-PCR sequencing could provide additional value by increasing the sensitivity of the assay compared with standard-PCR/Sanger sequencing. One possible explanation for lack of detection by LNA-PCR is the described genotypic mosaicism of mutant and nonmutant cells within the lesion. As demonstrated by Kuznetsov et al, 16 there is a tight inverse correlation between the percentage mutant colonyforming unit fibroblast versus age of FD patients, suggesting progressive demise of mutant stem cells caused by exuberant apoptosis. This "normalization" phenomenon replaces the mutant cells that are unable to regenerate with nonmutant cells leading to formation of normal bone. Interestingly, we found identical median and average ages for both groups of positive and negative GNAS exon 8 mutations in our patients. Also, no significant association was seen between age and mutational status in both decalcified and nondecalcified groups ( Table 3) . In our study, decalcification was the major limiting factor. There was a clear difference in the clinical sensitivity between the nondecalcified specimen group and specimens pretreated with decalcification (74% vs. 31%, P = 0.002) ( Table 4 ). Also, neither specimen size nor type (biopsy vs. resection) showed significant correlation with the mutational status in the tested samples (P = 0.356, 9 20 31 Z score = 3.081; P = 0.002 Z score was used to compare between the sensitivities in both decalcified and calcified groups. GNAS indicates G-nucleotide binding protein-a subunit; LNA-PCR, locked nucleic acid polymerase chain reaction. P = 0.456, respectively). This reinforces the fact that DNA quality is more important than quantity for sequencing method. Older and recent samples showed similar rates of positive and negative cases; there was no apparent effect of age of the specimen on the standard and LNA-PCR results. All of our decalcified samples underwent acid treatment using formic acid. EDTA sequesters metallic ions, including calcium in aqueous solution and acts as a chelating factor that can be used for decalcification. EDTA decalcification has been shown to provide better DNA quality for molecular studies. 23 Yet, the duration of this decalcification protocol remains an impediment to implement in routine practice.
Overall, our results are in agreement with the previously reported literature in terms of type of substitutions identified. Indeed, the most commonly identified p.R201H and p.R201C mutations constituted 62% and 30% of the positive cases, respectively.
Overall, GNAS exon 8 mutations are accepted as very specific to FD among all fibroosseous lesions. Until recently, GNAS exon 8 mutations have been reported in only 1 case outside of FD and its morphologic variants. 7, 8, 24 Pollandt et al 24 reported an R201C mutation in 1 FD-like low-grade central osteosarcoma. A very recent study of 9 parosteal osteosarcomas by Carter and colleagues revealed activating GNAS mutations in 3 osteosarcomas with dedifferentiation and 2 low-grade osteosarcomas (n = 5, 55%) using direct sequencing. The mutations included 4 R201C-mutated tumors and 1 tumor with an R201H mutation. On the basis of these results, the authors concluded that GNAS R201 mutation is not specific for FD and may not be as valuable as it was thought to be. 25 None of the low-grade central or parosteal osteosarcomas in our study showed GNAS exon 8 mutations.
In conclusion, GNAS mutational analysis remains a valuable adjunct method for the diagnosis of FD. Decalcification is one of the major limiting factors in molecular testing in FD. Highly sensitive methods such as LNA do not add additional advantage for mutation detection. Finally, as proposed by some authors, tumorigenesis in FD cases negative for activating GNAS mutations may be due to alternative pathways.
